Pulmonary therapy
Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate After Dual and Triple Therapy in Spain: A Sub-Study of the ORESTES Study.
Juan Marco Figueira-Gonçalves, Bernardino Alcázar-Navarrete, Raquel Casitas-Mateo, Jessica González, Carolina María Gotera-Rivera, Alberto Herrejón-Silvestre, Juan Margallo-Iribarnegaray, Marta Martín-Lana, Abel Pallarés-Sanmartín, Sergi Pascual-Guardia, Alberto Saura-Vinuesa, Carmen Corregidor-García, Eunice Fitas, Joaquín Sánchez-Covisa
Published: 202610.1007/s41030-026-00341-6
Abstract
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a progressive lung condition associated with high morbidity and mortality. Single-inhaler triple therapy (SITT), such as budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF), is r…
Preview only. Read the full abstract at the source